|
Update Article |
The
Hong Kong Practitioner VOLUME 24 / February
2002
| ||||
|
Management of stroke in the new millennium R T K Ho 何定國
| |||||
|
Summary
Stroke (brain attack) is the number 3 killer worldwide. It is the leading cause of disability in adults. It is estimated that up to one half of all strokes can be prevented through stroke risk detection and risk management. Therefore in spite of new and exciting treatments for acute stroke, prevention remains the key objective.. |
摘要
|
|
R T K Ho, MBBS(HK),
MRCP(UK), FRCP(Edin.), FHKAM Correspondence
to :
|
Introduction In Hong Kong each year, stroke (brain attack) claims about 3500 lives and about 16,000 people suffer a new or recurrent stroke each year. Stroke is the third leading cause of death behind heart disease and cancer. The major stroke subtypes are cerebral infarction (ischaemic stroke), intracerebral haemorrhage (ICH) and subarachnoid haemorrhage (Figure 1). The incidence of various stroke subtypes is listed in (Figure 2). ICH is more common in the Chinese population. About 50% of ICH are due to hypertension. The subtypes of ischaemic strokes are listed in (Figure 3), with lacunar infarction predominating.1 This paper will deal mainly with the management of ischaemic strokes, and touch only briefly on ICH.
|
|
|
|||||||||||||
|
Intracerebral haemorrhage (ICH) ICH accounts for about 24% of the major stroke subtypes and is more prevalent in the Chinese population. All patients presenting with symptoms of stroke must be screened for haemorrhage. CT remains the best diagnostic tool. The management of ICH remains controversial but important guidelines exist. The majority of ICH can be managed conservatively even though surgery may have a beneficial and life saving role in specific situations. Surgery is usually indicated in the following scenarios:
|
|
|
||||||||||
|
Most neurosurgeons will not intervene when:
Ischaemic stroke Management strategies for ischaemic stroke come under 3 major headings:
Stroke risk detection and risk management Non-modifiable risks factors These factors, although 'non-modifiable', help identify individuals who are at high risk of stroke and who would benefit from rigorous prevention and treatment of modifiable risk factors. Age
Sex
Race
and family history Well-documented modifiable risks factors Hypertension
Smoking
Hyperlipidaemia
Carotid
stenosis
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
Atrial
Fibrillation (AF)
|
| Figure 8: Decision Algorithm for Warfarin Therapy14 |
![]() |
|
Other
cardiac diseases
|
|
Less well-documented or potentially modifiable risk factors Obesity Lack
of physical activity Alcohol
Diet/nutrition
Drug
abuse Hormone
replacement therapy Oral
contraceptive usage
Antiplatelet therapy for stroke Meta-analysis data from multiple randomised trials showed that antiplatelet therapy reduced the risk of non fatal stroke and vascular death by 25% in patients at high risk for occlusive vascular disease.19 The commonly available antiplatelet agents include Aspirin, Dipyridamole, Ticlopodine and Clopidogrel. Their sites of action are shown below (Figure 9). Aspirin has proven effectiveness for stroke prevention in doses as low as 30mg/day. Both Ticlopodine and Clopidogrel have a slight advantage over aspirin in reducing stroke risk but Ticlopodine has the disadvantage of requiring blood monitoring in the initial phase of treatment. The European Stroke Prevention Study 2 showed the combination of aspirin 50mg/day with dipyridamole 400mg/day to be very effective in stroke prevention.
|
| Figure 9: Actions of available Antiplatelet Agents |
![]() |
|
Thrombolysis for acute ischaemic stroke Pathophysiology of ischaemic stroke Progressive reduction of cerebral blood flow leads to a continuum of metabolic and ionic disturbances which eventually ends in brain cell death. Animal models backed by human Positron Emission Tomography (PET) studies have shown that regional cerebral blood flow (rCBF) below 12ml/100g/min results in necrosis whereas only transient neurological deficits occur when rCBF remains above 22ml/100g/min. Tissue with rCBF between 12 and 22ml/100g/min represents the ischaemic penumbra an area of decompromised parenchyma surrounding the ischaemic core which has the potential for recovery, but only if blood flow is rapidly reestablished. Other factors such as collateral blood circulation and duration of blood flow reduction are also important in determining the final outcome of an ischaemic event.
|
|
Thrombolysis with tissue plasminogen activator (TPA) for acute ischaemic stroke TPA is an enzyme produced by recombinant DNA technology. It converts plasminogen to plasmin within the thrombus resulting in clot lysis. In 1996 the FDA approved TPA for the treatment of acute ischaemic stroke within the first 3 hours of acute stroke onset. This was based on the findings of the National Institute of Neurological Disorders and Stroke (NINDS) -TPA trials which showed significant improvement of stroke outcome in treated patients.20 The treated group showed statistically significant results in all four endpoints i.e. National Institute of Health Stroke Scale (NIHSS), Modified Rankin Scale, Barthel Index and Glasgow Coma Outcome. There was also lower mortality and 1 year follow up demonstrated that the treated group was more likely to have minimal or no disability. It is estimated that TPA treatment increases the chance of making a good neurologic recovery by about 30%. The main inclusion criteria for thrombolytic therapy are:
Contraindications to TPA treatment include:
Stroke
MRI
|
||||||
| Figure 11: Stroke MRI: Fast stroke examination carried out under 10 minutes. | |
![]() |
Note
1. : Absence of ischaemic change on the conventional MRI (Grase) at 2 hours 2. : Mismatch between diffusion weighted image (DWI-I) and perfusion time to peak image (TTP) image indicating potentially salvageable penumbral tissue |
|
Acute stroke unit Since a time window of 3 hours is critical for the success of thrombolytic therapy, this type of treatment is best carried out in hospitals with an Acute Stroke Unit and a dedicated team of doctors. The stroke team, headed by a neurologist should include a neurosurgeon, a neuro-radiologist, an on call medical officer, and a co-ordinating nursing officer. The team is notified by a common "code stroke" paging system on the imminent arrival of a potential stroke patient. The initial clinical assessment, followed by CT scan and Stroke MRI must all be performed within the 3 hour time window (Figure 12).
Symptom Recognition should lead to Rapid action to get the patient to hospital where a full assessment including CT and Stroke MRI can be performed within one hour of admission. A decision can then be made as to whether Revascularisation with TPA is indicated.
|
|
Patient and public education programme In North America, it is estimated that only 3-13% of stroke patients successfully receive thrombolytic therapy. The implementation of TPA therapy for Hong Kong stroke patients remains in serious doubt. Firstly, there is a severe lack of Acute Stroke Units in government hospitals where the majority of stroke patients are likely to present. Secondly, Acute Stroke Units place huge logistic demands on hospitals in terms of costs, manpower and scanning facilities and are therefore unlikely to be welcomed in government based A & E Departments with high existing work loads. Complementing this is the low level of stroke awareness amongst the Hong Kong public. This became evident in a survey commissioned by the Brain Centre in January 2001 and conducted by the Hong Kong Institute of Asia - Pacific Study at the Chinese University of Hong Kong (unpublished). The results of the survey carried out on 643 adults showed the majority (94.7%) had little or no knowledge of stroke. The majority did not know the warning signs nor the long term effects of stroke. Almost 100% did not know the first 3-6 hours after stroke onset is most critical for effective management. Eighty percent expressed an urgent need for special facilities for treatment and prevention of stroke. An aggressive on going public education and stroke awareness programme will be essential to raise the level of stroke knowledge in Hong Kong. Hopefully, by the time this is implemented, the standard of stroke care in Hong Kong will also have improved so that patients presenting with acute stroke symptoms will have the opportunity of receiving TPA treatment. In addition, public education will lea)d to more effective stroke prevention, which should always remain the primary goal and forefront of stroke management.
|
|
Key messages
|
|
References
|